Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC

Recently, the ADAURA study demonstrated statistically significant improved disease-free survival (DFS) with adjuvant osimertinib in patients with resected stage IB-IIIA non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation. A consistent improvement in disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Brazel, Danielle, Nagasaka, Misako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126226/
https://www.ncbi.nlm.nih.gov/pubmed/35615402
http://dx.doi.org/10.2147/LCTT.S346922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126226/
https://www.ncbi.nlm.nih.gov/pubmed/35615402
http://dx.doi.org/10.2147/LCTT.S346922

Ejemplares similares